Fuller & Thaler Asset Management Inc. Increases Stake in Henry Schein, Inc. (NASDAQ:HSIC)

Fuller & Thaler Asset Management Inc. grew its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 7.2% during the 4th quarter, HoldingsChannel reports. The firm owned 48,189 shares of the company’s stock after buying an additional 3,256 shares during the quarter. Fuller & Thaler Asset Management Inc.’s holdings in Henry Schein were worth $3,335,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC increased its stake in shares of Henry Schein by 6.9% in the 3rd quarter. Barclays PLC now owns 286,475 shares of the company’s stock valued at $20,882,000 after purchasing an additional 18,458 shares in the last quarter. Virtu Financial LLC acquired a new stake in Henry Schein in the third quarter valued at approximately $239,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Henry Schein in the third quarter valued at approximately $109,000. Tidal Investments LLC raised its stake in shares of Henry Schein by 54.9% during the 3rd quarter. Tidal Investments LLC now owns 13,942 shares of the company’s stock worth $1,016,000 after buying an additional 4,939 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Henry Schein by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 37,637 shares of the company’s stock valued at $2,673,000 after buying an additional 4,621 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Activity

In related news, Director Philip A. Laskawy sold 2,604 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the transaction, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now owns 62,688 shares of the company’s stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $65.17 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The business’s 50 day moving average price is $69.21 and its 200 day moving average price is $71.78. The company has a market cap of $7.98 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 2.13 and a beta of 0.84. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period in the previous year, the firm posted $0.66 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. On average, research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

HSIC has been the subject of several recent analyst reports. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Barrington Research restated an “outperform” rating and set a $90.00 price target on shares of Henry Schein in a research report on Wednesday, February 26th. UBS Group lowered their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Jefferies Financial Group increased their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Finally, Wells Fargo & Company assumed coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.